Prog stock: Short squeeze | Understand short squeeze | float short

 Oct. 18, 2021

My notes: 

1. Google Fintel's Short Squeeze leaderboard - Prog, score of 97.43
2. 
   

Why Progenity Stock Is Soaring on Tuesday

The biotech stock, which has had a volatile year, is a favorite of retail investors because of its potential for a short squeeze.

Jim Halley

(TMFjimhalley)

Oct 12, 2021 at 3:50PM

Key Points

• Progenity lost $78.5 million in the second quarter.
• The company's stock has been heavily shorted.
• It received a patent last month for a prenatal test.

What happened

Progenity (NASDAQ:PROG

×​

) saw its shares rise more than 11% on Tuesday. The company's stock opened at $2.10 a share, then rose to as high as $2.70 a share in midday trading. The stock has been volatile. It is down more than 74% for the year but is up more than 128% the past three months. It is well off its 52-week high of $9.48 a share.

) saw its shares rise more than 11% on Tuesday. The company's stock opened at $2.10 a share, then rose to as high as $2.70 a share in midday trading. The stock has been volatile. It is down more than 74% for the year but is up more than 128% the past three months. It is well off its 52-week high of $9.48 a share.

So what

The biotech company specializes in molecular testing products. Its last real news was last month when it announced it was able to patent Preecludia, its test to rule out preeclampsia, which is when pregnant women or new mothers develop high blood pressure and high protein levels that can cause complications with the liver, kidneys, the lungs or even seizures. The company's assay measures for free and dissociated placental growth factor, a biomarker for preeclampsia. At this point, Preecludia is still in clinical testing.

With no big news coming out for more than a month, the reason for the stock's rise is likely that retail investors see its potential for a short squeeze. It tops the list for Fintel's Short Squeeze leaderboard with a score of 97.43.

Now what

The stock is a gamble because it is a young company with little revenue and only a few products, mostly prenatal screening tests. In the second quarter, it reported revenue of $463,000, up $1,772% year over year, but it had a net loss of $78.5 million compared to a loss of $32.3 million in the same period in 2020. It said it plans to cut costs to focus on its pipeline.

It does have a decent-sized pipeline in women's health, gastrointestinal health, and oral biotherapeutics. For the time being, it is pinning a lot of hope on getting Preecludia approved. If that happens, it would be the first single test to rule out preeclampsia, which is one of the leading causes of maternal morbidity.

Like many early-stage biotech companies, there are a lot of ifs in Progenity's future. It's safe to say that investing in the stock is risky, in the short term or long term.